Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.
Teva Pharmaceutical Industries' (NYSE:TEVA) investors will be pleased with their impressive 228% return over the last three years [Yahoo! Finance]
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an "overweight" rating on the stock.